Amgen Presents New Data From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma At ASCO 2017

Jun 4, 2017 - (Newswire)

- Amgen (NASDAQ: AMGN) today announced new data from the XGEVA® (denosumab) Phase 3 '482 study, the largest international multiple myeloma trial ever conducted. The study met its primary endpoint, demonstrating XGEVA is non-inferior to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma (HR=0.98, 95 percent CI: 0.85, 1.14; p=0.01). The analysis demonstrated that patients on XGEVA had a significantly lower rate of renal adverse events compared to zoledronic acid (10.0 percent versus 17.1 percent, p

Original Source: https://www.newswire.com/news/amgen-presents-new-data-from-phase-3-xgeva-denosumab-study-in-patients-with

What Next?

Related Articles

Leave a Reply

Submit Comment